Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Capital Expenditures: 2016-2025

Historic Capital Expenditures for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $1.3 million.

  • Ultragenyx Pharmaceutical's Capital Expenditures fell 20.96% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year decrease of 32.25%. This contributed to the annual value of $7.5 million for FY2024, which is 83.08% down from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its Capital Expenditures stood at $1.3 million for Q3 2025, which was down 42.38% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Capital Expenditures ranged from a high of $32.2 million in Q1 2022 and a low of $654,000 during Q4 2024.
  • For the 3-year period, Ultragenyx Pharmaceutical's Capital Expenditures averaged around $5.2 million, with its median value being $2.0 million (2024).
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's Capital Expenditures soared by 443.92% in 2021, and later crashed by 94.07% in 2023.
  • Quarterly analysis of 5 years shows Ultragenyx Pharmaceutical's Capital Expenditures stood at $16.0 million in 2021, then spiked by 68.06% to $27.0 million in 2022, then crashed by 94.07% to $1.6 million in 2023, then crashed by 59.13% to $654,000 in 2024, then declined by 20.96% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $2.2 million for Q2 2025, and $1.6 million during Q1 2025.